Grand Pharmaceutical Group Limited (0512.HK)
HKD 5.91
(0.34%)
HKD 5.91
(0.34%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 2.96 Billion HKD | 4.91% |
| 2022 | 3.09 Billion HKD | 23.51% |
| 2021 | 3.1 Billion HKD | 31.27% |
| 2020 | 2.41 Billion HKD | 9.31% |
| 2019 | 1.86 Billion HKD | 45.61% |
| 2018 | 1.32 Billion HKD | 24.14% |
| 2017 | 976.62 Million HKD | 34.26% |
| 2016 | 715.07 Million HKD | 23.48% |
| 2015 | 589.09 Million HKD | 16.35% |
| 2014 | 494.92 Million HKD | 64.6% |
| 2013 | 316.67 Million HKD | 22.14% |
| 2012 | 237.54 Million HKD | 36.39% |
| 2011 | 178.6 Million HKD | -30.08% |
| 2010 | 245.81 Million HKD | 166.47% |
| 2009 | 92.24 Million HKD | 1434.65% |
| 2008 | 6.01 Million HKD | 116.34% |
| 2007 | -35.98 Million HKD | -232.27% |
| 2006 | 3.64 Million HKD | 87.85% |
| 2005 | -141 Million HKD | 20.18% |
| 2004 | -114.19 Million HKD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | 1.62 Billion HKD | 0.0% |
| 2023 FY | - HKD | 4.91% |
| 2023 Q2 | 1.72 Billion HKD | 0.0% |
| 2023 Q4 | 1.32 Billion HKD | 0.0% |
| 2022 FY | - HKD | 23.51% |
| 2022 Q2 | 1.51 Billion HKD | 0.0% |
| 2022 Q4 | 1.47 Billion HKD | 0.0% |
| 2021 Q4 | 1.1 Billion HKD | 0.0% |
| 2021 FY | - HKD | 31.27% |
| 2021 Q2 | 1.2 Billion HKD | 0.0% |
| 2020 Q4 | 864.95 Million HKD | 0.0% |
| 2020 Q2 | 922.56 Million HKD | 0.0% |
| 2020 FY | - HKD | 9.31% |
| 2019 Q4 | 853.21 Million HKD | 0.0% |
| 2019 FY | - HKD | 45.61% |
| 2019 Q2 | 797.36 Million HKD | 0.0% |
| 2018 FY | - HKD | 24.14% |
| 2018 Q2 | 637.84 Million HKD | 0.0% |
| 2018 Q4 | 490.77 Million HKD | 0.0% |
| 2017 FY | - HKD | 34.26% |
| 2017 Q2 | 467.63 Million HKD | 0.0% |
| 2017 Q4 | 441.49 Million HKD | 0.0% |
| 2016 Q4 | 353.74 Million HKD | 0.0% |
| 2016 Q2 | 323.42 Million HKD | 0.0% |
| 2016 FY | - HKD | 23.48% |
| 2015 Q4 | 296.97 Million HKD | 0.0% |
| 2015 Q2 | 251.42 Million HKD | 0.0% |
| 2015 FY | - HKD | 16.35% |
| 2014 Q4 | 264.35 Million HKD | 0.0% |
| 2014 Q2 | 206.95 Million HKD | 0.0% |
| 2014 FY | - HKD | 64.6% |
| 2013 Q4 | 167.18 Million HKD | 0.0% |
| 2013 FY | - HKD | 22.14% |
| 2013 Q2 | 119.16 Million HKD | 0.0% |
| 2012 Q2 | 50.03 Million HKD | 0.0% |
| 2012 FY | - HKD | 36.39% |
| 2012 Q4 | 77.83 Million HKD | 55.55% |
| 2012 Q3 | 50.03 Million HKD | 0.0% |
| 2012 Q1 | 50.03 Million HKD | 0.0% |
| 2011 Q2 | 34.86 Million HKD | 0.0% |
| 2011 Q3 | 34.86 Million HKD | 0.0% |
| 2011 Q4 | 50.03 Million HKD | 43.53% |
| 2011 FY | - HKD | -30.08% |
| 2011 Q1 | 34.86 Million HKD | 0.0% |
| 2010 Q1 | 47.37 Million HKD | 0.0% |
| 2010 Q3 | 47.37 Million HKD | 0.0% |
| 2010 Q4 | 34.86 Million HKD | -26.42% |
| 2010 FY | - HKD | 166.47% |
| 2010 Q2 | 47.37 Million HKD | 0.0% |
| 2009 Q1 | 19.66 Million HKD | 0.0% |
| 2009 Q3 | 19.66 Million HKD | 0.0% |
| 2009 Q4 | 47.37 Million HKD | 140.86% |
| 2009 FY | - HKD | 1434.65% |
| 2009 Q2 | 19.66 Million HKD | 0.0% |
| 2008 Q2 | 1.11 Million HKD | 0.0% |
| 2008 Q4 | 19.66 Million HKD | 1663.71% |
| 2008 Q1 | 1.11 Million HKD | 0.0% |
| 2008 FY | - HKD | 116.34% |
| 2008 Q3 | 1.11 Million HKD | 0.0% |
| 2007 Q1 | -8.73 Million HKD | 0.0% |
| 2007 Q4 | 1.11 Million HKD | 112.77% |
| 2007 Q3 | -8.73 Million HKD | 0.0% |
| 2007 Q2 | -8.73 Million HKD | 0.0% |
| 2007 FY | - HKD | -232.27% |
| 2006 Q4 | -8.73 Million HKD | -1762.15% |
| 2006 FY | - HKD | 87.85% |
| 2006 Q2 | -469 Thousand HKD | 0.0% |
| 2006 Q3 | -469 Thousand HKD | 0.0% |
| 2006 Q1 | -469 Thousand HKD | 0.0% |
| 2005 Q2 | -21.26 Million HKD | 0.0% |
| 2005 Q4 | -469 Thousand HKD | 97.79% |
| 2005 FY | - HKD | 20.18% |
| 2005 Q1 | -21.26 Million HKD | 0.0% |
| 2005 Q3 | -21.26 Million HKD | 0.0% |
| 2004 Q2 | -28.54 Million HKD | 0.0% |
| 2004 Q3 | -28.54 Million HKD | 0.0% |
| 2004 Q1 | -28.54 Million HKD | 0.0% |
| 2004 Q4 | -21.26 Million HKD | 25.5% |
| 2004 FY | - HKD | 0.0% |
| 2003 Q4 | -28.54 Million HKD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Pak Fah Yeow International Limited | 150.4 Million HKD | -1872.447% |
| Extrawell Pharmaceutical Holdings Limited | -129.51 Million HKD | 2390.426% |
| Wai Yuen Tong Medicine Holdings Limited | 113.79 Million HKD | -2506.865% |
| Qianhai Health Holdings Limited | -50.22 Million HKD | 6006.07% |
| Lee's Pharmaceutical Holdings Limited | 109.82 Million HKD | -2601.293% |
| Essex Bio-Technology Limited | 418.37 Million HKD | -609.064% |
| Tongfang Kontafarma Holdings Limited | 76.63 Million HKD | -3771.126% |
| PuraPharm Corporation Limited | -26.16 Million HKD | 11436.161% |
| SSY Group Limited | 2.11 Billion HKD | -40.292% |
| JBM (Healthcare) Limited | 204.39 Million HKD | -1351.421% |
| Jacobson Pharma Corporation Limited | 429.92 Million HKD | -590.024% |
| China Resources Pharmaceutical Group Limited | 15.43 Billion HKD | 80.775% |